J. Goldman & Co LP - CATALYST PHARMACEUTICALS INC ownership

CATALYST PHARMACEUTICALS INC's ticker is CPRX and the CUSIP is 14888U101. A total of 143 filers reported holding CATALYST PHARMACEUTICALS INC in Q2 2020. The put-call ratio across all filers is 0.10 and the average weighting 0.1%.

Quarter-by-quarter ownership
J. Goldman & Co LP ownership history of CATALYST PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$157,815
-97.8%
13,500
-97.4%
0.01%
-97.7%
Q2 2023$7,078,875
+286.4%
526,702
+376.7%
0.26%
+247.3%
Q1 2023$1,831,891
+267.1%
110,488
+2.4%
0.07%
+138.7%
Q2 2020$499,000
-71.5%
107,951
-76.3%
0.03%
-85.3%
Q1 2020$1,751,000454,7730.21%
Other shareholders
CATALYST PHARMACEUTICALS INC shareholders Q2 2020
NameSharesValueWeighting ↓
TANAKA CAPITAL MANAGEMENT INC 589,883$590,0001.38%
Broadfin Capital, LLC 8,200,000$8,610,0000.96%
Avoro Capital Advisors LLC 1,141,149$1,198,0000.24%
CORRADO ADVISORS, LLC 190,600$200,0000.12%
Baker Brothers Advisors 5,102,153$5,357,0000.05%
KINGDON CAPITAL MANAGEMENT, L.L.C. 756,311$794,0000.04%
Point72 Asset Management, L.P. 2,272,816$2,386,0000.02%
AGRAN LIBBIE 44,000$46,0000.01%
COMPTON CAPITAL MANAGEMENT INC /RI 10,000$11,0000.01%
KENNEDY CAPITAL MANAGEMENT LLC 233,171$245,0000.00%
View complete list of CATALYST PHARMACEUTICALS INC shareholders